Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model
- PMID: 17457304
- DOI: 10.1038/sj.pcan.4500971
Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model
Abstract
Transgenic (TG) rats bearing a probasin promoter/simian virus 40 T antigen (SV40 Tag) construct were treated with antiandrogens to examine their ability to suppress prostate carcinogenesis. Finasteride and flutamide were administered to 10-week-old TG rats five times a week for 2, 5 and 7 weeks. Antiandrogen-treated prostates exhibited atrophic glandular structures with almost no expression of SV40 Tag and only weak signals for androgen receptors. Furthermore, quantitative data for ventral prostate adenocarcinomas showed significant decrease with antiandrogen treatment. Both finasteride and flutamide had the ability to suppress SV40 Tag-driven carcinogenesis through their different antiandrogenic mechanisms, suggesting that this TG model is suitable for exploring the potential of agents to inhibit prostate cancer development.
Similar articles
-
Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.Cancer Res. 2000 Aug 1;60(15):4093-7. Cancer Res. 2000. PMID: 10945615
-
Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.Carcinogenesis. 2005 Jun;26(6):1109-16. doi: 10.1093/carcin/bgi056. Epub 2005 Feb 24. Carcinogenesis. 2005. PMID: 15731164
-
Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: lack of influence of carcinogen or testosterone treatment.Cancer Sci. 2003 Feb;94(2):153-7. doi: 10.1111/j.1349-7006.2003.tb01412.x. Cancer Sci. 2003. PMID: 12708490 Free PMC article.
-
Molecular profiles of finasteride effects on prostate carcinogenesis.Cancer Prev Res (Phila). 2009 Jun;2(6):518-24. doi: 10.1158/1940-6207.CAPR-08-0241. Epub 2009 Jun 2. Cancer Prev Res (Phila). 2009. PMID: 19491289 Review.
-
Biochemical recurrence of prostate cancer.Curr Probl Cancer. 2003 Sep-Oct;27(5):243-72. doi: 10.1016/s0147-0272(03)00032-1. Curr Probl Cancer. 2003. PMID: 12963877 Review. No abstract available.
Cited by
-
Preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice.PLoS One. 2013 Oct 18;8(10):e77738. doi: 10.1371/journal.pone.0077738. eCollection 2013. PLoS One. 2013. PMID: 24204943 Free PMC article.
-
Establishment of an invasive prostate cancer model in transgenic rats by intermittent testosterone administration.J Toxicol Pathol. 2014 Apr;27(1):43-9. doi: 10.1293/tox.2013-0052. Epub 2014 Apr 30. J Toxicol Pathol. 2014. PMID: 24791066 Free PMC article.
-
Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence.J Carcinog. 2011;10:27. doi: 10.4103/1477-3163.90438. Epub 2011 Nov 30. J Carcinog. 2011. PMID: 22190869 Free PMC article.
-
Exploring experimental models of prostate cancer in chemoprevention: Oxidative stress as a key pathway to translational research.Pathol Int. 2025 Mar;75(3):131-144. doi: 10.1111/pin.13509. Epub 2025 Jan 14. Pathol Int. 2025. PMID: 39807695 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous